DK1140061T3 - Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi - Google Patents

Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi

Info

Publication number
DK1140061T3
DK1140061T3 DK99964320T DK99964320T DK1140061T3 DK 1140061 T3 DK1140061 T3 DK 1140061T3 DK 99964320 T DK99964320 T DK 99964320T DK 99964320 T DK99964320 T DK 99964320T DK 1140061 T3 DK1140061 T3 DK 1140061T3
Authority
DK
Denmark
Prior art keywords
gamma
narcolepsy
treatment
disclosed
formulations
Prior art date
Application number
DK99964320T
Other languages
English (en)
Inventor
Harry N Cook
Martha Hamilton
Doug Danielson
Colette Goderstad
Dayton Reardan
Original Assignee
Orphan Medical Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=22351244&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=DK1140061(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Orphan Medical Inc filed Critical Orphan Medical Inc
Application granted granted Critical
Publication of DK1140061T3 publication Critical patent/DK1140061T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/14—Esters of carboxylic acids, e.g. fatty acid monoglycerides, medium-chain triglycerides, parabens or PEG fatty acid esters
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61J—CONTAINERS SPECIALLY ADAPTED FOR MEDICAL OR PHARMACEUTICAL PURPOSES; DEVICES OR METHODS SPECIALLY ADAPTED FOR BRINGING PHARMACEUTICAL PRODUCTS INTO PARTICULAR PHYSICAL OR ADMINISTERING FORMS; DEVICES FOR ADMINISTERING FOOD OR MEDICINES ORALLY; BABY COMFORTERS; DEVICES FOR RECEIVING SPITTLE
    • A61J1/00—Containers specially adapted for medical or pharmaceutical purposes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/191—Carboxylic acids, e.g. valproic acid having two or more hydroxy groups, e.g. gluconic acid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02—Inorganic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
    • A61K47/12—Carboxylic acids; Salts or anhydrides thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0087—Galenical forms not covered by A61K9/02 - A61K9/7023
    • A61K9/0095—Drinks; Beverages; Syrups; Compositions for reconstitution thereof, e.g. powders or tablets to be dispersed in a glass of water; Veterinary drenches
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/20—Hypnotics; Sedatives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Addiction (AREA)
  • Psychiatry (AREA)
  • Dermatology (AREA)
  • Inorganic Chemistry (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Pain & Pain Management (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pulmonology (AREA)
  • Psychology (AREA)
  • Anesthesiology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
DK99964320T 1998-12-23 1999-12-22 Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi DK1140061T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11374598P 1998-12-23 1998-12-23
PCT/US1999/030740 WO2000038672A2 (en) 1998-12-23 1999-12-22 Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Publications (1)

Publication Number Publication Date
DK1140061T3 true DK1140061T3 (da) 2003-08-25

Family

ID=22351244

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99964320T DK1140061T3 (da) 1998-12-23 1999-12-22 Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi

Country Status (11)

Country Link
US (14) US6472431B2 (da)
EP (1) EP1140061B1 (da)
JP (2) JP4374441B2 (da)
AT (1) ATE238783T1 (da)
AU (1) AU779354B2 (da)
CA (1) CA2355293C (da)
DE (1) DE69907508T2 (da)
DK (1) DK1140061T3 (da)
ES (1) ES2193777T3 (da)
IL (2) IL143733A0 (da)
WO (1) WO2000038672A2 (da)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy
DE10315640A1 (de) * 2003-04-04 2004-10-14 Ignatov, Konstantin Verfahren zur kontrollierten Freisetzung von Komponenten in eine Lösung
EP1629732A1 (en) * 2004-08-27 2006-03-01 Purac Biochem BV Composition for inactivating yeasts or molds in soft drinks
US20060069040A1 (en) * 2004-09-07 2006-03-30 Mortimer Mamelak GHB compositions
US20090137565A1 (en) * 2004-11-10 2009-05-28 The Trustees Of Columbia University In The City Of New York Method for treatment of movement disorders
US7838556B2 (en) * 2006-02-21 2010-11-23 University Of Maryland, Baltimore Ethers of 3-hydroxyphenylacetic acid as selective gamma-hydroxybutyric acid receptor ligands
WO2007124949A1 (en) * 2006-05-01 2007-11-08 Universiteit Gent Hydroxybutyrate and poly-hydroxybutyrate as components of animal feed or feed additives
BRPI0602825A2 (pt) * 2006-06-23 2012-04-24 Rhodia Br Ltda formulação de pó efervescente auto-refrigerante para bebidas e uso de formulação em pó efervescente
US8524944B2 (en) * 2008-04-15 2013-09-03 Norac Pharma Process for the preparation of sodium gamma-hydroxybutyrate
US8771735B2 (en) * 2008-11-04 2014-07-08 Jazz Pharmaceuticals, Inc. Immediate release dosage forms of sodium oxybate
US8778398B2 (en) * 2008-11-04 2014-07-15 Jazz Pharmaceuticals, Inc. Immediate release formulations and dosage forms of gamma-hydroxybutyrate
FR2938431B1 (fr) * 2008-11-14 2013-12-20 Debregeas Et Associes Pharma Nouvelle composition a base d'acide gamma-hydroxybutyrique
US8410304B2 (en) * 2009-04-15 2013-04-02 Norac Pharma Process for preparing gamma-hydroxybutyrate
FR2949061B1 (fr) 2009-08-12 2013-04-19 Debregeas Et Associes Pharma Microgranules flottants
FR2949062B1 (fr) 2009-08-12 2011-09-02 Debregeas Et Associes Pharma Nouvelles formulations pharmaceutiques contre le mesusage des medicaments
AU2011232408B2 (en) 2010-03-24 2015-07-30 Jazz Pharmaceuticals, Inc. Controlled release dosage forms for high dose, water soluble and hygroscopic drug substances
EP2598137B1 (en) * 2010-07-29 2022-07-06 Ecolab USA Inc. Method of treating animal drinking water with interval dosing of a biocide
US20160068463A1 (en) * 2012-11-14 2016-03-10 Metabolix, Inc. Production of salts of 4-hydroxybutyrate using biobased raw materials
US8591922B1 (en) * 2012-12-14 2013-11-26 Jazz Pharmacuticals, Inc. Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
WO2014096984A1 (en) 2012-12-21 2014-06-26 Wockhardt Limited Stable pharmaceutical composition of sodium oxybate
WO2014127053A2 (en) 2013-02-13 2014-08-21 Metabolix, Inc. Process for ultra pure chemical production from biobased raw starting materials
US9050302B2 (en) * 2013-03-01 2015-06-09 Jazz Pharmaceuticals Ireland Limited Method of administration of gamma hydroxybutyrate with monocarboxylate transporters
US9801852B2 (en) * 2013-08-30 2017-10-31 Jazz Pharmaceuticals, Inc. Devices and methods for facilitating and controlling use of a medication
AU2015326472B2 (en) 2014-09-29 2020-05-28 Zogenix International Limited Control system for control of distribution of medication
US10398662B1 (en) 2015-02-18 2019-09-03 Jazz Pharma Ireland Limited GHB formulation and method for its manufacture
US9750811B2 (en) 2015-09-15 2017-09-05 Boveda, Inc. Devices and methods for controlling headspace humidity and oxygen levels
WO2017050259A1 (en) 2015-09-23 2017-03-30 Xw Laboratories Inc. Prodrugs of gamma-hydroxybutyric acid, compositions and uses thereof
WO2017112701A1 (en) 2015-12-22 2017-06-29 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
JP6893213B2 (ja) 2015-12-22 2021-06-23 ゾゲニクス インターナショナル リミテッド フェンフルラミン組成物およびその調製法
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11000498B2 (en) 2016-07-22 2021-05-11 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
RU2746000C2 (ru) 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US10195151B2 (en) 2016-09-06 2019-02-05 Jazz Pharmaceuticals International Iii Limited Formulations of (R)-2-amino-3-phenylpropyl carbamate
EP3509582B1 (en) 2016-09-06 2023-12-20 Axsome Malta Ltd. Solvate form of (r)-2-amino-3-phenylpropyl carbamate
MY202185A (en) 2016-10-06 2024-04-15 Jazz Pharmaceuticals Ireland Ltd Carbamoyl phenylalaninol compounds and uses therof
EP3851098B1 (en) 2016-10-12 2022-12-21 Drug Plastics & Glass Company, Inc. Container assembly with predetermined humidity
US20180263936A1 (en) * 2017-03-17 2018-09-20 Jazz Pharmaceuticals Ireland Limited Gamma-hydroxybutyrate compositions and their use for the treatment of disorders
US20180303821A1 (en) * 2017-04-24 2018-10-25 BraneQuest, Inc. Membrane active molecules
CA3065522A1 (en) 2017-06-02 2018-12-06 Jazz Pharmaceuticals Ireland Limited Methods and compositions for treating excessive sleepiness
US11413264B2 (en) 2017-07-31 2022-08-16 Jazz Pharmaceuticals Ireland Limited Carbamoyl phenylalaninol analogs and uses thereof
US10682317B2 (en) 2017-09-26 2020-06-16 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11337920B2 (en) 2017-12-18 2022-05-24 Tris Pharma, Inc. Pharmaceutical composition comprising GHB gastro-retentive raft forming systems having trigger pulse drug release
IL275312B1 (en) 2017-12-18 2024-05-01 Tris Pharma Inc GHB pharmacy preparations containing a system that creates a floating integrated penetrating polymer network
WO2019126218A1 (en) 2017-12-18 2019-06-27 Tris Pharma, Inc. Modified release drug powder composition comprising gastro-retentive raft forming systems having trigger pulse drug release
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
CA3115122A1 (en) 2018-11-19 2020-05-28 Jazz Pharmaceuticals Ireland Limited Alcohol-resistant drug formulations
GB201821066D0 (en) * 2018-12-21 2019-02-06 Univ Oxford Innovation Ltd Sleep modulation
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
US20210186907A1 (en) * 2019-12-24 2021-06-24 Jazz Pharmaceuticals Ireland Limited Ghb dosing
CN114946259A (zh) 2020-02-13 2022-08-26 中兴通讯股份有限公司 随机接入过程中前导码和有效载荷消息的传输
TW202139986A (zh) 2020-02-21 2021-11-01 愛爾蘭商爵士製藥愛爾蘭有限責任公司 治療原發性嗜睡症之方法
US10940133B1 (en) 2020-03-19 2021-03-09 Jazz Pharmaceuticals Ireland Limited Methods of providing solriamfetol therapy to subjects with impaired renal function
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
CN116261451A (zh) 2020-07-24 2023-06-13 凯瑞康宁生物工程有限公司 γ-羟基丁酸衍生物的药物组合物和药物动力学
CA3194665A1 (en) 2020-10-05 2022-04-14 Jia-Ning Xiang Modified release compositions of a gamma-hydroxybutyric acid derivative
US20230404950A1 (en) 2020-10-08 2023-12-21 Jazz Pharmaceuticals Ireland Limited Sodium oxybate to treat idiopathic hypersomnia
CA3195856A1 (en) 2020-10-16 2022-04-21 Franck SKOBIERANDA Treatment methods using ghb
CN117098533A (zh) 2021-03-19 2023-11-21 凯瑞康宁公司 γ-羟基丁酸衍生物的组合释放型制剂的药物动力学
WO2023062018A1 (en) 2021-10-11 2023-04-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US20230118007A1 (en) * 2021-10-18 2023-04-20 Synovent Laboratories, LLC Medical devices and systems for use
WO2023135150A1 (en) 2022-01-11 2023-07-20 Jazz Pharmaceuticals Ireland Limited Method of administering oxybate
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal
WO2023178288A1 (en) 2022-03-17 2023-09-21 Azora Therapeutics, Inc. Companion diagnostics and strategies for treatment with an aryl hydrocarbon receptor agonist compound

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3051619A (en) 1960-05-19 1962-08-28 Equilibre Biolog L 4-hydroxy butyric acid therapeutic compositions and process of use for clinical sedation, hypnosis, or anaesthesia
GB922029A (en) * 1960-05-19 1963-03-27 Equilibre Biolog L Therapeutic composition
US4183916A (en) 1978-03-31 1980-01-15 Beecham Inc. Oral compositions
US4374441A (en) * 1980-05-23 1983-02-22 Book Covers, Inc. Method of making a book cover and pocket element therefor
EP0044801B1 (de) 1980-07-17 1984-02-15 Josef Dr. Klosa Nichthygroskopische Salze der 4-Hydroxybuttersäure, Verfahren zu ihrer Herstellung und ihre Verwendung zur Herstellung pharmazeutischer Mittel
ZA814854B (en) 1980-07-17 1982-07-28 J Klosa Nonhygroscopic salts of 4-hydroxybutryric acid, methods of their production and pharmaceutical preparations containing these salts
EP0235408B1 (en) 1984-08-06 1991-01-09 The University Of Toronto Innovations Foundation Pharmaceutical composition and treatment
US4738985A (en) 1986-03-19 1988-04-19 The University Of Toronto Innovations Foundations Pharmaceutical composition and treatment
US5210083A (en) 1986-07-17 1993-05-11 Ed. Geistlich Sohne A.G. Fur Chemische Industrie Pharmaceutical compositions
IT1217783B (it) * 1988-06-03 1990-03-30 Farmaceutico Ct S R L Lab Impiego di salo dell,acido gamma idrossi butirrico per la preparazione di composizioni farmaceutiche adatta ad essereimpiegate nella terapia dell,alcolismo e composizioni relative
IL93618A0 (en) 1989-03-06 1990-12-23 Lilly Co Eli Improved diluent formulation for daptomycin
JP2564690B2 (ja) 1990-06-14 1996-12-18 三省製薬 株式会社 メラニン生成抑制外用剤
DE4113984C2 (de) 1991-04-29 2002-05-08 Koehler Chemie Dr Franz Salze der 4-Hydroxy-Buttersäure
US5286497A (en) 1991-05-20 1994-02-15 Carderm Capital L.P. Diltiazem formulation
IT1248588B (it) 1991-06-28 1995-01-19 Gaetano Crepaldi Composizioni farmaceutiche per la terapia dell'astinenza, del " craving", della dipendenza da sostanze stupefacenti, da sostanze psicoattive, da nicotina e dei disturbi alimentari.
US5371424A (en) 1992-11-25 1994-12-06 Motorola, Inc. Transmitter/receiver circuit and method therefor
IT1271403B (it) * 1993-03-26 1997-05-28 Ct Lab Farm Srl Sali dell'acido gamma-idrossibutirrico ad attivita' ansiolitica e per il trattamento degli stati depressivi
IT1266565B1 (it) 1993-07-22 1997-01-09 Ct Lab Farm Srl Composizioni farmaceutiche a rilascio controllato a base di uno o piu' sali farmaceuticamente accettabili dell'acido gamma-idrossi-butirrico.
US5840331A (en) * 1995-06-07 1998-11-24 Arch Development Corporation Use of γ-hydroxybutyrate for the stimulation of sleep-related secretion growth hormone and prolactin
US6077545A (en) 1995-10-30 2000-06-20 Matrix Pharmaceuticals, Inc. Process and composition for therapeutic cisplatin (CDDP)
DE19602664A1 (de) 1996-01-25 1997-08-07 Waltenberger Karl Hans Mittel zum Inhibieren des Algenwachstums
SI0914158T2 (sl) 1996-04-05 2006-04-30 Takeda Chemical Industries Ltd Farmacevtska kombinacija, ki vsebuje spojino z angiotenzin II-antagonisticno aktivnostjo in spojino, ki povecuje inzulinsko obcutljivost
IT1283782B1 (it) * 1996-08-09 1998-04-30 Ct Lab Farm Srl Uso di ammidi dell'acido gamma-idrossibutirrico nel trattamento di tossicodipendenze,ed in particolare sell'alcolismo
JP3390179B2 (ja) 1996-08-15 2003-03-24 シェーリング コーポレイション エーテルムスカリン様アンタゴニスト
US20080292700A1 (en) 1997-04-21 2008-11-27 Biovail Laboratories Controlled release formulations using intelligent polymers
US5990162A (en) * 1997-08-29 1999-11-23 Orphan Medical, Inc. Method for treatment of fibromyalgia and chronic fatigue syndrome
WO2000038672A2 (en) 1998-12-23 2000-07-06 Orphan Medical, Inc. Microbiologically sound and stable solutions of gamma-hydroxybutyrate salt for the treatment of narcolepsy

Also Published As

Publication number Publication date
US6780889B2 (en) 2004-08-24
US9539330B2 (en) 2017-01-10
JP5204685B2 (ja) 2013-06-05
EP1140061B1 (en) 2003-05-02
US20120202879A1 (en) 2012-08-09
US20150073052A1 (en) 2015-03-12
US20160058862A1 (en) 2016-03-03
US8952062B2 (en) 2015-02-10
US8263650B2 (en) 2012-09-11
IL143733A0 (en) 2002-04-21
US8859619B2 (en) 2014-10-14
US6472431B2 (en) 2002-10-29
DE69907508D1 (de) 2003-06-05
CA2355293A1 (en) 2000-07-06
US20070270491A1 (en) 2007-11-22
US7262219B2 (en) 2007-08-28
JP2009167189A (ja) 2009-07-30
US8461203B2 (en) 2013-06-11
ATE238783T1 (de) 2003-05-15
WO2000038672A3 (en) 2000-11-09
JP4374441B2 (ja) 2009-12-02
US20040209955A1 (en) 2004-10-21
AU779354B2 (en) 2005-01-20
US20120020833A1 (en) 2012-01-26
DE69907508T2 (de) 2003-11-20
IL143733A (en) 2006-10-31
AU2059000A (en) 2000-07-31
US20130143965A1 (en) 2013-06-06
US20130267595A1 (en) 2013-10-10
JP2002533388A (ja) 2002-10-08
US20020077334A1 (en) 2002-06-20
WO2000038672A2 (en) 2000-07-06
US20190328882A1 (en) 2019-10-31
CA2355293C (en) 2005-08-16
US8324275B2 (en) 2012-12-04
US20110039929A1 (en) 2011-02-17
US20120202880A1 (en) 2012-08-09
EP1140061A2 (en) 2001-10-10
US20170224825A1 (en) 2017-08-10
US7851506B2 (en) 2010-12-14
US20030125385A1 (en) 2003-07-03
ES2193777T3 (es) 2003-11-01

Similar Documents

Publication Publication Date Title
DK1140061T3 (da) Mikrobiologisk sunde og stabile opløsninger af gamma-hydroxybutyratsalt til behandling af narcolepsi
PT1333887E (pt) Metodo de tratamento de desordens musculares
NZ515567A (en) Method for treating chronic pain using MEK inhibitors
DK0867184T3 (da) Anvendelse af tiagabin til behandling af søvnforstyrrelser
DE60111053D1 (de) Flexibles verbindungsstück zur stabilisierung der wirbelsäule
BR0108452A (pt) Inibidores da oxidação parcial de ácido graxo no tratamento de insuficiência cardìaca congestiva
MY133667A (en) Quinazoline ditosylate salt compounds
IS6560A (is) Lyfjasamsetning fyrir meðhöndlun á bráðum, þrálátum sársauka og/eða taugakerfissársauka og mígreni
DE50014190D1 (de) Verwendung von phthalazin-derivaten zur behandlung neurodegenerativer krankheiten
WO2003030819A3 (en) Tetracycline derivatives and methods of use thereof
HK1051499A1 (en) Method for treating ocular pain
TR200000755T2 (tr) Karşıt olma-karşı gelme bozukluğunun tedavisi.
CY1107640T1 (el) Μεθοδος για πιστοποιηση παραγοντων για τη θεραπεια διαβητη
HK1075403A1 (en) Treatment of mastalgia with 4-hydroxy tamoxifen
EP1889614A3 (en) Methods of using rapid-onset selective serotonin reuptake inhibitors for treating sexual dysfunction
DK1261333T3 (da) Anvendelse af topiramate for behandling og diagnosticering af sövnbesværet vejrtrækning og midler for udförsel af behandlingen og diagnosticeringen
WO2002005642A3 (en) Synergistic biocidal compositions
FI20000635A0 (fi) COMT-inhibiittoreiden käyttö analgeettina
DE50111407D1 (de) Mittel enthaltend n-chlortaurin sowie dessen verwendung zur behandlung von schleimhautpolypen
AU2002347984A1 (en) Use of norepinephrine reuptake inhibitors for the treatment of tic disorders
AU2976095A (en) Use of selegilin in the treatment of epileptic conditions
DE60143390D1 (de) Methode zur behandlung von herzinsuffizienz
WO2005021095A3 (en) Treatment of stuttering and other communication disorders with norepinephrine reuptake inhibitors
UA38347A (uk) Горілка особлива "банкетна учта"
AP2000001959A0 (en) Treatment of generalized anxiety disorder with paroxetine.